|
Clinical characteristics of women with and without BRCA founder mutations |
|||||
| Variable |
No BRCA founder mutation (n = 440) |
BRCA1 founder mutation (n = 43)† |
P (BRCA1 versus no founder mutation)* |
BRCA2 founder mutation (n = 14)† |
P (BRCA2 versus no founder mutation)* |
|
|
|||||
| Age at diagnosis (years) |
|||||
| < 50 |
135 (31%) |
30 (70%) |
< 0.0001 |
4 (29%) |
NS |
| ≥ 50 |
305 (69%) |
13 (30%) |
10 (71%) |
||
| Tumor size |
|||||
| T1 |
324 (74%) |
29 (67%) |
NS |
8 (57%) |
NS |
| T2 |
97 (22%) |
11 (26%) |
4 (29%) |
||
| Unknown |
19 (4%) |
3 (7%) |
2 (14%) |
||
| Nodal involvement |
|||||
| Present |
149 (34%) |
18 (42%) |
NS |
6 (43%) |
NS |
| Absent |
262 (60%) |
23 (53%) |
6 (43%) |
||
| Unknown |
29 (6%) |
2 (5%) |
2 (14%) |
||
| Estrogen receptor |
|||||
| Positive |
197 (45%) |
6 (14%) |
< 0.0001 |
7 (50%) |
NS |
| Negative |
98 (22%) |
27 (63%) |
3 (21%) |
||
| Unknown |
145 (33%) |
10 (23%) |
4 (29%) |
||
| Chemotherapy |
|||||
| Yes |
156 (35%) |
24 (56%) |
0.02 |
7 (50%) |
NS |
| No |
257 (58%) |
17 (40%) |
7 (50%) |
||
| Unknown |
27 (10%) |
2 (4%) |
0 (0%) |
||
| Tamoxifen |
|||||
| Yes |
190 (43%) |
10 (23%) |
0.01 |
9 (64%) |
NS |
| No |
203 (46%) |
30 (70%) |
5 (36%) |
||
| Unknown |
47 (11%) |
3 (7%) |
0 (0%) |
||
|
*Cases in which the characteristic of interest is unknown are not included in the comparisons. †Woman with both BRCA1 and BRCA2 founder mutations are included in both groups, hence the total number women listed here is 497. | |||||
Robson et al. Breast Cancer Res 2004 6:R8 doi:10.1186/bcr658 |
|||||